Invariant NKT cells as novel targets for immunotherapy in solid tumors

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Pilones, Karsten A ^a   Aryankalayil, Joseph ^a   Demaria, Sandra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALPHA GALACTOSYLCERAMIDE; CYTOKINE; GLYCOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR ANTIGEN; VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; AUTOIMMUNITY; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TH1 CELL; TUMOR IMMUNITY; VACCINATION; ANIMAL; IMMUNOLOGY; METHODOLOGY; NATURAL KILLER T CELL; NEOPLASM;

ANIMALS; HUMANS; IMMUNOTHERAPY; NATURAL KILLER T-CELLS; NEOPLASMS;

EID: 84868705788     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/720803     Document Type: Review

References (116)

1. Lantz O., Bendelac A., An invariant T cell receptor α chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. Journal of Experimental Medicine 1994 180 3 1097 1106 2-s2.0-0028025074 10.1084/jem.180.3.1097 (Pubitemid 24256622)
2. Porcelli S., Yockey C. E., Brenner M. B., Balk S. P., Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- α / β T cells demonstrates preferential use of several V β genes and an invariant TCR α chain. Journal of Experimental Medicine 1993 178 1 1 16 2-s2.0-0027178514 (Pubitemid 23173239)
3. Cardell S., Tangri S., Chan S., Kronenberg M., Benoist C., Mathis D., CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. Journal of Experimental Medicine 1995 182 4 993 1004 2-s2.0-0029112507 10.1084/jem.182.4.993
4. Godfrey D. I., MacDonald H. R., Kronenberg M., Smyth M. J., Van Kaer L., NKT cells: what's in a name? Nature Reviews Immunology 2004 4 3 231 237 2-s2.0-1542511203 (Pubitemid 38339089)
5. Ambrosino E., Terabe M., Halder R. C., Peng J., Takaku S., Miyake S., Yamamura T., Kumar V., Berzofsky J. A., Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. Journal of Immunology 2007 179 8 5126 5136 2-s2.0-36049022618
6. Berzofsky J. A., Terabe M., NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. Journal of Immunology 2008 180 6 3627 3635 2-s2.0-44849083151
7. Bendelac A., CD1: presenting unusual antigens to unusual T lymphocytes. Science 1995 269 5221 185 186 2-s2.0-0029072786
8. Roark J. H., Park S. H., Jayawardena J., Kavita U., Shannon M., Bendelac A., CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. Journal of Immunology 1998 160 7 3121 3127 2-s2.0-0032055980 (Pubitemid 28164699)
9. Bendelac A., Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. Journal of Experimental Medicine 1995 182 6 2091 2096 2-s2.0-0028863822 10.1084/jem.182.6.2091
10. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M., CD1d-restricted and TCR-mediated activation of V(α)14 NKT cells by glycosylceramides. Science 1997 278 5343 1626 1629 2-s2.0-0030696696 10.1126/science.278.5343.1626 (Pubitemid 27516282)
11. Crowe N. Y., Uldrich A. P., Kyparissoudis K., Hammond K. J. L., Hayakawa Y., Sidobre S., Keating R., Kronenberg M., Smyth M. J., Godfrey D. I., Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. Journal of Immunology 2003 171 8 4020 4027 2-s2.0-0141958207 (Pubitemid 37238677)
12. Zhou D., Mattner J., Cantu C. III, Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y. P., Yamashita T., Teneberg S., Wang D., Proia R. L., Levery S. B., Savage P. B., Teyton L., Bendelac A., Lysosomal glycosphingolipid recognition by NKT cells. Science 2004 306 5702 1786 1789 2-s2.0-10044280324 10.1126/science.1103440 (Pubitemid 39601398)
13. Mannik L. A., Chin-Yee I., Sharif S., van Kaer L., Delovitch T. L., Haeryfar S. M. M., Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses. Immunology 2011 132 3 361 375 2-s2.0-79251616955 10.1111/j.1365-2567.2010.03369. x
14. Joyce S., Woods A. S., Yewdell J. W., Bennink J. R., de Silva A. D., Boesteanu A., Balk S. P., Cotter R. J., Brutkiewicz R. R., Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 1998 279 5356 1541 1544 2-s2.0-0032489652 10.1126/science.279.5356.1541 (Pubitemid 28217078)
15. Pei B., Speak A. O., Shepherd D., Butters T., Cerundolo V., Platt F. M., Kronenberg M., Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids. Journal of Immunology 2011 186 3 1348 1360 2-s2.0-79251564431 10.4049/jimmunol.1001008
16. Porubsky S., Speak A. O., Luckow B., Cerundolo V., Platt F. M., Gröne H. J., Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proceedings of the National Academy of Sciences of the United States of America 2007 104 14 5977 5982 2-s2.0-34247592222 10.1073/pnas.0611139104 (Pubitemid 47175644)
17. Chang D. H., Deng H., Matthews P., Krasovsky J., Ragupathi G., Spisek R., Mazumder A., Vesole D. H., Jagannath S., Dhodapkar M. V., Inflammation- associated lysophospholipids as ligands for CDld-restricted T cells in human cancer. Blood 2008 112 4 1308 1316 2-s2.0-51649127569 10.1182/blood-2008-04- 149831
18. Fox L. M., Cox D. G., Lockridge J. L., Wang X., Chen X., Scharf L., Trott D. L., Ndonye R. M., Veerapen N., Besra G. S., Howell A. R., Cook M. E., Adams E. J., Hildebrand W. H., Gumperz J. E., Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biology 2009 7 10 2-s2.0-70350503426 10.1371/journal.pbio.1000228 e1000228
19. Brennan P. J., Tatituri R. V. V., Brigl M., Kim E. Y., Tuli A., Sanderson J. P., Gadola S. D., Hsu F. F., Besra G. S., Brenner M. B., Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nature Immunology 2011 12 12 1202 1211 2-s2.0-81255208437 10.1038/ni.2143
20. Wu D. Y., Segal N. H., Sidobre S., Kronenberg M., Chapman P. B., Cross-presentation of disialoganglioside GD3 to natural killer T cells. Journal of Experimental Medicine 2003 198 1 173 181 2-s2.0-0038152830 10.1084/jem.20030446 (Pubitemid 36870197)
21. Blomqvist M., Rhost S., Teneberg S., Löfbom L., Oterbye T., Brigl M., Mansson J. E., Cardell S. L., Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. European Journal of Immunology 2009 39 7 1726 1735 2-s2.0-69249095385 10.1002/eji.200839001
22. Jahng A., Maricic I., Aguilera C., Cardell S., Halder R. C., Kumar V., Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. Journal of Experimental Medicine 2004 199 7 947 957 2-s2.0-1842682026 10.1084/jem.20031389 (Pubitemid 38481086)
23. Buschard K., Blomqvist M., Osterbye T., Fredman P., Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia 2005 48 10 1957 1962 2-s2.0-26244466348 10.1007/s00125-005-1926-9 (Pubitemid 41416902)
24. Wu D., Xing G. W., Poles M. A., Horowitz A., Kinjo Y., Sullivan B., Bodmer-Narkevitch V., Plettenburg O., Kronenberg M., Tsuji M., Ho D. D., Wong C. H., Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proceedings of the National Academy of Sciences of the United States of America 2005 102 5 1351 1356 2-s2.0-13444255993 10.1073/pnas.0408696102 (Pubitemid 40209173)
25. Kinjo Y., Wu D., Kim G., Xing G. W., Poles M. A., Ho D. D., Tsuji M., Kawahara K., Wong C. H., Kronenberg M., Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005 434 7032 520 525 2-s2.0-15844421595 10.1038/nature03407 (Pubitemid 40477061)
26. Mattner J., DeBord K. L., Ismail N., Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005 434 525 529 (Pubitemid 40477062)
27. Sriram V., Du W., Gervay-Hague J., Brutkiewicz R. R., Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. European Journal of Immunology 2005 35 6 1692 1701 2-s2.0-20844463676 10.1002/eji.200526157 (Pubitemid 40862317)
28. Kinjo Y., Illarionov P., Vela J. L., Pei B., Girardi E., Li X., Li Y., Imamura M., Kaneko Y., Okawara A., Miyazaki Y., Gómez-Velasco A., Rogers P., Dahesh S., Uchiyama S., Khurana A., Kawahara K., Yesilkaya H., Andrew P. W., Wong C. H., Kawakami K., Nizet V., Besra G. S., Tsuji M., Zajonc D. M., Kronenberg M., Invariant natural killer T cells recognize glycolipids from pathogenic gram-positive bacteria. Nature Immunology 2011 12 10 966 974 2-s2.0-80052966551 10.1038/ni.2096
29. Yoshimoto T., Bendelac A., Watson C., Hu-Li J., Paul W. E., Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production. Science 1995 270 5243 1845 1847 2-s2.0-0029562066
30. Hammond K. J. L., Pelikan S. B., Crowe N. Y., Randle-Barrett E., Nakayama T., Taniguchi M., Smyth M. J., van Driel I. R., Scollay R., Baxter A. G., Godfrey D. I., NKT cells are phenotypically and functionally diverse. European Journal of Immunology 1999 29 11 3768 3781 2-s2.0-0032744350 10.1002/(SICI)1521-4141(199911)29:113768::AID-IMMU3768>3.0.CO;2-G (Pubitemid 29527827)
31. Lee P. T., Benlagha K., Teyton L., Bendelac A., Distinct functional lineages of human V α 24 natural killer T cells. Journal of Experimental Medicine 2002 195 5 637 641 2-s2.0-0037018108 10.1084/jem.20011908 (Pubitemid 34461508)
32. Uldrich A. P., Crowe N. Y., Kyparissoudis K., Pellicci D. G., Zhan Y., Lew A. M., Bouillet P., Strasser A., Smyth M. J., Godfrey D. I., NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. Journal of Immunology 2005 175 5 3092 3101 2-s2.0-23844457565 (Pubitemid 41170529)
33. Hayakawa Y., Takeda K., Yagita H., Van Kaer L., Saiki I., Okumura K., Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. Journal of Immunology 2001 166 10 6012 6018 2-s2.0-0035873434 (Pubitemid 32440726)
34. Fujii S. I., Liu K., Smith C., Bonito A. J., Steinman R. M., The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. Journal of Experimental Medicine 2004 199 12 1607 1618 2-s2.0-3042545974 10.1084/jem.20040317 (Pubitemid 38821994)
35. Durgan K., Ali M., Warner P., Latchman Y. E., Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Cancer Immunology, Immunotherapy 2011 60 4 547 558 2-s2.0-79953789685 10.1007/s00262-010-0963-5
36. Chang W. S., Kim J. Y., Kim Y. J., Kim Y. S., Lee J. M., Azuma M., Yagita H., Kang C. Y., Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. Journal of Immunology 2008 181 10 6707 6710 2-s2.0-58149189061
37. Terabe M., Berzofsky J. A., Chapter 8 the role of NKT cells in tumor immunity. Advances in Cancer Research 2008 101 277 348 2-s2.0-56849090964 10.1016/S0065-230X(08)00408-9
38. Wu L., van Kaer L., Natural killer T cells and autoimmune disease. Current Molecular Medicine 2009 9 1 4 14 2-s2.0-62749198174 10.2174/ 156652409787314534
39. Tessmer M. S., Fatima A., Paget C., Trottein F., Brossay L., NKT cell immune responses to viral infection. Expert Opinion on Therapeutic Targets 2009 13 2 153 162 2-s2.0-64349106545 10.1517/14712590802653601
40. Smyth M. J., Thia K. Y. T., Street S. E. A., Cretney E., Trapani J. A., Taniguchi M., Kawano T., Pelikan S. B., Crowe N. Y., Godfrey D. I., Differential tumor surveillance by natural killer (NK) and NKT cells. Journal of Experimental Medicine 2000 191 4 661 668 2-s2.0-0034695880 10.1084/jem.191.4.661
41. Crowe N. Y., Smyth M. J., Godfrey D. I., A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. Journal of Experimental Medicine 2002 196 1 119 127 2-s2.0-0036645278 10.1084/jem.20020092 (Pubitemid 34747317)
42. Smyth M. J., Crowe N. Y., Pellicci D. G., Kyparissoudis K., Kelly J. M., Takeda K., Yagita H., Godfrey D. I., Sequential production of interferon- γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α -galactosylceramide. Blood 2002 99 4 1259 1266 2-s2.0-0037082487 10.1182/blood.V99.4.1259 (Pubitemid 34547079)
43. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., Kondo E., Harada M., Koseki H., Nakayama T., Tanaka Y., Taniguchi M., Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V α 14 NKT cells. Proceedings of the National Academy of Sciences of the United States of America 1998 95 10 5690 5693 2-s2.0-13144249230 10.1073/pnas.95.10.5690 (Pubitemid 28224157)
44. Hayakawa Y., Rovero S., Forni G., Smyth M. J., α -galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2003 100 16 9464 9469 2-s2.0-0041422186 10.1073/pnas. 1630663100 (Pubitemid 37033951)
45. Motoki K., Nakagawa R., Nakamura H., Antitumor activities of KRN7000 in liver metastases models. Annals of Oncology 1998 9 supplement 2 80 89 10.1093/annonc/9.suppl2.80
46. Nakagawa R., Motoki K., Nakamura H., Ueno H., Iijima R., Yamauchi A., Tsuyuki S., Inamoto T., Koezuka Y., Antitumor activity of α -galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncology Research 1998 10 11-12 561 568 2-s2.0-0032242177
47. Metelitsa L. S., Weinberg K. I., Emanuel P. D., Seeger R. C., Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003 17 6 1068 1077 2-s2.0-0038040624 10.1038/sj.leu.2402943 (Pubitemid 36722236)
48. Renukaradhya G. J., Khan M. A., Vieira M., Du W., Gervay-Hague J., Brutkiewicz R. R., Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008 111 12 5637 5645 2-s2.0-47049090132 10.1182/blood-2007-05-092866
49. Uemura Y., Liu T. Y., Narita Y., Suzuki M., Nakatsuka R., Araki T., Matsumoto M., Iwai L. K., Hirosawa N., Matsuoka Y., Murakami M., Kimura T., Hase M., Kohno H., Sasaki Y., Ichihara Y., Ishihara O., Kikuchi H., Sakamoto Y., Jiao S. C., Senju S., Sonoda Y., Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of V α 24 invariant NKT cells. Journal of Immunology 2009 183 1 201 208 2-s2.0-68949117875 10.4049/jimmunol.0900873
50. Yang Y. F., Tomura M., Ono S., Hamaoka T., Fujiwara H., Requirement for IFN- γ in IL-12 production induced by collaboration between V α 14+ NKT cells and antigen-presenting cells. International Immunology 2000 12 12 1669 1675 2-s2.0-0034535655 (Pubitemid 32007723)
51. Fujii S. I., Shimizu K., Smith C., Bonifaz L., Steinman R. M., Activation of natural killer T cells by α -galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. Journal of Experimental Medicine 2003 198 2 267 279 2-s2.0-0037787982 10.1084/jem.20030324 (Pubitemid 36987852)
52. Kitamura H., Iwakabe K., Yahata T., Nishimura S. I., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., van Kaer L., Kawano T., Taniguchi M., Nishimura T., The natural killer T (NKT) cell ligand α -galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. Journal of Experimental Medicine 1999 189 7 1121 1128 2-s2.0-0033526066 10.1084/jem.189.7.1121 (Pubitemid 29169829)
53. Shimaoka T., Seino K. I., Kume N., Minami M., Nishime C., Suematsu M., Kita T., Taniguchi M., Matsushima K., Yonehara S., Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. Journal of Immunology 2007 179 12 8172 8179 2-s2.0-40049104573
54. Germanov E., Veinotte L., Cullen R., Chamberlain E., Butcher E. C., Johnston B., Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. Journal of Immunology 2008 181 1 81 91 2-s2.0-47949107462
55. Metelitsa L. S., Naidenko O. V., Kant A., Wu H. W., Loza M. J., Perussia B., Kronenberg M., Seeger R. C., Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. Journal of Immunology 2001 167 6 3114 3122 2-s2.0-0035884974 (Pubitemid 32852549)
56. Taniguchi M., Harada M., Kojo S., Nakayama T., Wakao H., The regulatory role of V α 14 NKT cells in innate and acquired immune response. Annual Review of Immunology 2003 21 483 513 2-s2.0-0038228956 10.1146/annurev.immunol. 21.120601.141057 (Pubitemid 37174539)
57. Smyth M. J., Godfrey D. I., NKT cells and tumor immunitya double-edged sword. Nature Immunology 2000 1 6 459 460 2-s2.0-0034572835
58. O'Konek J. J., Illarionov P., Khursigara D. S., Ambrosino E., Izhak L., Castillo B. F., Raju R., Khalili M., Kim H. Y., Howell A. R., Besra G. S., Porcelli S. A., Berzofsky J. A., Terabe M., Mouse and human iNKT cell agonist β -mannosylceramide reveals a distinct mechanism of tumor immunity. Journal of Clinical Investigation 2011 121 2 683 694 2-s2.0-79551572107 10.1172/JCI42314
59. Schneiders F. L., de Bruin R. C. G., Santegoets S. J. A. M., Activated iNKT cells promote V γ 9V δ 2-T cell anti-tumor effector functions through the production of TNF- α Clinical Immunology 2012 142 2 194 200 10.1016/j.clim.2011.10.006
60. Hong C., Lee H., Park Y. K., Shin J., Jung S., Kim H., Hong S., Park S. H., Regulation of secondary antigen-specific CD8+ T-cell responses by natural killer T cells. Cancer Research 2009 69 10 4301 4308 2-s2.0-66249124296 10.1158/0008-5472.CAN-08-1721
61. Shin Y., Hong C., Lee H., Shin J. H., Hong S., Park S. H., NKT cell-dependent regulation of secondary antigen-specific, conventional CD4+ T cell immune responses. Journal of Immunology 2010 184 10 5589 5594 2-s2.0-77954738648 10.4049/jimmunol.0903121
62. Sica A., Bronte V., Altered macrophage differentiation and immune dysfunction in tumor development. Journal of Clinical Investigation 2007 117 5 1155 1166 2-s2.0-34248172324 10.1172/JCI31422 (Pubitemid 46718400)
63. Song L., Asgharzadeh S., Salo J., Engell K., Wu H. W., Sposto R., Ara T., Silverman A. M., DeClerck Y. A., Seeger R. C., Metelitsa L. S., V α 24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. Journal of Clinical Investigation 2009 119 6 1524 1536 2-s2.0-66349083007 10.1172/JCI37869
64. Hong D. S., Angelo L. S., Kurzrock R., Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007 110 9 1911 1928 2-s2.0-35648995976 10.1002/cncr.22999 (Pubitemid 350036849)
65. Falcone M., Facciotti F., Ghidoli N., Monti P., Olivieri S., Zaccagnino L., Bonifacio E., Casorati G., Sanvito F., Sarvetnick N., Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. Journal of Immunology 2004 172 10 5908 5916 2-s2.0-2442542307 (Pubitemid 38621189)
66. Mizuno M., Masumura M., Tomi C., Chiba A., Oki S., Yamamura T., Miyake S., Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. Journal of Autoimmunity 2004 23 4 293 300 2-s2.0-9644259041 10.1016/j.jaut.2004. 09.008 (Pubitemid 39574804)
67. Kaieda S., Tomi C., Oki S., Yamamura T., Miyake S., Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis and Rheumatism 2007 56 6 1836 1845 2-s2.0-34447523766 10.1002/art.22714 (Pubitemid 47110383)
68. Miellot-Gafsou A., Biton J., Bourgeois E., Herbelin A., Boissier M. C., Bessis N., Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology 2010 130 2 296 306 2-s2.0-77952076809 10.1111/j.1365-2567.2009.03235.x
69. van de Keere F., Tonegawa S., CD4+ T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. Journal of Experimental Medicine 1998 188 10 1875 1882 2-s2.0-0032538820 10.1084/jem.188.10.1875 (Pubitemid 28536775)
70. Singh A. K., Wilson M. T., Hong S., Olivares-Villagómez D., Du C., Stanic A. K., Joyce S., Sriram S., Koezuka Y., van Kaer L., Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2001 194 12 1801 1811 2-s2.0-0035905471 10.1084/jem.194.12.1801 (Pubitemid 34028659)
71. Miyamoto K., Miyake S., Yamamura T., A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001 413 6855 531 534 2-s2.0-0035807302 10.1038/35097097 (Pubitemid 32938752)
72. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D. D., Carbone D. P., Paul W. E., Berzofskv J. A., NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology 2000 1 6 515 520 2-s2.0-0034569025
73. Renukaradhya G. J., Sriram V., Du W., Gervay-Hague J., van Kaer L., Brutkiewicz R. R., Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. International Journal of Cancer 2006 118 12 3045 3053 2-s2.0-33646435567 10.1002/ijc.21764
74. Bricard G., Cesson V., Devevre E., Bouzourene H., Barbey C., Rufer N., Im J. S., Alves P. M., Martinet O., Halkic N., Cerottini J. C., Romero P., Porcelli S. A., MacDonald H. R., Speiser D. E., Enrichment of human CD4+ V α 24/V β 11 invariant NKT cells in intrahepatic malignant tumors. Journal of Immunology 2009 182 8 5140 5151 2-s2.0-65249176389 10.4049/jimmunol.0711086
75. Mi Q. S., Ly D., Zucker P., McGarry M., Delovitch T. L., Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Diabetes 2004 53 5 1303 1310 2-s2.0-2342650811 10.2337/diabetes.53.5.1303 (Pubitemid 38569017)
76. Terabe M., Matsui S., Park J. M., Mamura M., Noben-Trauth N., Donaldson D. D., Chen W., Wahl S. M., Ledbetter S., Pratt B., Letterio J. J., Paul W. E., Berzofsky J. A., Transforming growth factor- β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. Journal of Experimental Medicine 2003 198 11 1741 1752 2-s2.0-10744220561 10.1084/jem.20022227 (Pubitemid 37494166)
77. Terabe M., Khanna C., Bose S., Melchionda F., Mendoza A., Mackall C. L., Helman L. J., Berzofsky J. A., CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor- β Cancer Research 2006 66 7 3869 3875 2-s2.0-33645732440 10.1158/0008-5472.CAN-05-3421
78. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., Godfrey D. I., Ostrand-Rosenberg S., Smyth M. J., Berzofsky J. A., A nonclassical non-V α 14J α 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. Journal of Experimental Medicine 2005 202 12 1627 1633 2-s2.0-29144484782 10.1084/jem.20051381 (Pubitemid 41815868)
79. Berzofsky J. A., Terabe M., A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunology, Immunotherapy 2008 57 11 1679 1683 2-s2.0-50649087259 10.1007/s00262-008-0495-4
80. Berzofsky J. A., Terabe M., The contrasting roles of NKT cells in tumor immunity. Current Molecular Medicine 2009 9 6 667 672 2-s2.0-70350546309 10.2174/156652409788970706
81. Pilones K. A., Kawashima N., Yang A. M., Babb J. S., Formenti S. C., Demaria S., Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clinical Cancer Research 2009 15 2 597 606 2-s2.0-59449094876 10.1158/1078-0432.CCR-08-1277
82. Aslakson C. J., Miller F. R., Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Research 1992 52 6 1399 1405 2-s2.0-0026503190
83. Demaria S., Kawashima N., Yang A. M., Devitt M. L., Babb J. S., Allison J. P., Formenti S. C., Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research 2005 11 2 I 728 734 2-s2.0-12244252335 (Pubitemid 40116901)
84. Hegde S., Lockridge J. L., Becker Y. A., Ma S., Kenney S. C., Gumperz J. E., Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands. Journal of Autoimmunity 2011 37 1 28 38 2-s2.0-79958046086 10.1016/j.jaut.2011.03.001
85. Hegde S., Fox L., Wang X., Gumperz J. E., Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 2010 130 4 471 483 2-s2.0-77954521483 10.1111/j.1365-2567.2010.03293.x
86. Hegde S., Jankowska-Gan E., Roenneburg D. A., Torrealba J., Burlingham W. J., Gumperz J. E., Human NKT cells promote monocyte differentiation into suppressive myeloid antigen-presenting cells. Journal of Leukocyte Biology 2009 86 4 757 768 2-s2.0-70349643100 10.1189/jlb.0209059
87. Hegde S., Chen X., Keaton J. M., Reddington F., Besra G. S., Gumperz J. E., NKT cells direct monocytes into a DC differentiation pathway. Journal of Leukocyte Biology 2007 81 5 1224 1235 2-s2.0-34247898819 10.1189/jlb.1206718 (Pubitemid 46702041)
88. Moreira-Teixeira L., Resende M., Devergne O., Herbeuval J. P., Hermine O., Schneider E., Dy M., Cordeiro-da-Silva A., Leite-de-Moraes M. C., Rapamycin combined with TGF- β converts human invariant NKT Cells into suppressive Foxp3+ regulatory cells. Journal of Immunology 2012 188 2 624 631 2-s2.0-84855999082 10.4049/jimmunol.1102281
89. Giaccone G., Punt C. J. A., Ando Y., Ruijter R., Nishi N., Peters M., Von Blomberg B. M. E., Scheper R. J., van der Vliet H. J. J., van den Eertwegh A. J. M., Roelvink M., Beijnen J., Zwierzina H., Pinedo H. M., A phase I study of the natural killer T-cell ligand α -galactosylceramide (KRN7000) in patients with solid tumors. Clinical Cancer Research 2002 8 12 3702 3709 2-s2.0-0036896332 (Pubitemid 35424759)
90. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., Shimizu N., Horiguchi S., Okamoto Y., Fujii S. I., Taniguchi M., Fujisawa T., Nakayama T., A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clinical Cancer Research 2006 12 20 6079 6086 2-s2.0-33750709275 10.1158/1078-0432.CCR-06-0114 (Pubitemid 44703772)
91. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., Iizasa T., Nakayama T., Taniguchi M., Fujisawa T., A phase I study of α -galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clinical Cancer Research 2005 11 5 1910 1917 2-s2.0-20144388064 10.1158/1078-0432.CCR-04-1453 (Pubitemid 40471857)
92. Uchida T., Horiguchi S., Tanaka Y., Yamamoto H., Kunii N., Motohashi S., Taniguchi M., Nakayama T., Okamoto Y., Phase I study of α -galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunology, Immunotherapy 2008 57 3 337 345 2-s2.0-37349014075 10.1007/s00262-007-0373-5 (Pubitemid 350295376)
93. Motohashi S., Nagato K., Kunii N., Yamamoto H., Yamasaki K., Okita K., Hanaoka H., Shimizu N., Suzuki M., Yoshino I., Taniguchi M., Fujisawa T., Nakayama T., A phase I-II study of α -galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. Journal of Immunology 2009 182 4 2492 2501 2-s2.0-61449255982 10.4049/jimmunol.0800126
94. Nagato K., Motohashi S., Ishibashi F., Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha galactosylceramide pulsed antigen presenting cells. Journal of Clinical Immunology 2012 32 5 1071 1081 10.1007/s10875-012-9697-9
95. Kunii N., Horiguchi S., Motohashi S., Combination therapy of in vitro expanded natural killer T cells and alpha galactosylceramide pulsed antigen presenting cells in patients with recurrent head and neck carcinoma. Cancer Science 2009 10 6 1092 1098 10.1111/j.1349-7006.2009.01135.x
96. Fujii S. I., Shimizu K., Kronenberg M., Steinman R. M., Prolonged IFN- γ -producing NKT response induced with α -galactosylceramide-loaded DCs. Nature Immunology 2002 3 9 867 874 2-s2.0-0036735859 10.1038/ni827
97. Toura I., Kawano T., Akutsu Y., Nakayama T., Ochiai T., Taniguchi M., Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α -galactosylceramide. Journal of Immunology 1999 163 5 2387 2391 2-s2.0-0033197917 (Pubitemid 29399156)
98. Molling J. W., Kolgen W., van der Vliet H. J., Peripheral blood IFN- γ -secreting V α 24+V β 11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. International Journal of Cancer 2005 116 1 87 93 10.1002/ijc.20998 (Pubitemid 40827759)
99. Tahir S. A. M., Cheng O., Shaulov A., Koezuka Y., Bubley G. J., Wilson S. B., Balk S. P., Exley M. A., Loss of IFN- γ production by invariant NK T cells in advanced cancer. Journal of Immunology 2001 167 7 4046 4050 2-s2.0-0035478706 (Pubitemid 32910851)
100. Imataki O., Heike Y., Makiyama H., Iizuka A., Ikarashi Y., Ishida T., Wakasugi H., Takaue Y., Insufficient ex vivo expansion of V α 24+ natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14+ cells. Cytotherapy 2008 10 5 497 506 2-s2.0-53249103247 10.1080/14653240802072747
101. Takahashi T., Nieda M., Koezuka Y., Nicol A., Porcelli S. A., Ishikawa Y., Tadokoro K., Hirai H., Juji T., Analysis of human V α 24+ CD4+ NKT cells activated by α -glycosylceramide-pulsed monocyte-derived dendritic cells. Journal of Immunology 2000 164 9 4458 4464 2-s2.0-0034193041 (Pubitemid 30238040)
102. Rogers P. R., Matsumoto A., Naidenko O., Kronenberg M., Mikayama T., Kato S., Expansion of human V α 24+ NKT cells by repeated stimulation with KRN7000. Journal of Immunological Methods 2004 285 2 197 214 2-s2.0-1242351228 10.1016/j.jim.2003.12.003 (Pubitemid 38224562)
103. Schmieg J., Yang G., Franck R. W., Tsuji M., Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α -galactosylceramide. Journal of Experimental Medicine 2003 198 11 1631 1641 2-s2.0-0345167831 10.1084/jem.20031192 (Pubitemid 37494156)
104. Teng M. W. L., Yue S., Sharkey J., Exley M. A., Smyth M. J., CD1d activation and blockade: a new antitumor strategy. Journal of Immunology 2009 182 6 3366 3371 2-s2.0-65449146344 10.4049/jimmunol.0802964
105. Teng M. W. L., Westwood J. A., Darcy P. K., Sharkey J., Tsuji M., Franck R. W., Porcelli S. A., Besra G. S., Takeda K., Yagita H., Kershaw M. H., Smyth M., Combined natural killer T-cell-based immunotherapy eradicates established tumors in mice. Cancer Research 2007 67 15 7495 7504 2-s2.0-34547628869 10.1158/0008-5472.CAN-07-0941 (Pubitemid 47206579)
106. Teng M. W. L., Sharkey J., McLaughlin N. M., Exley M. A., Smyth M. J., CD1d-based combination therapy eradicates established tumors in mice. Journal of Immunology 2009 183 3 1911 1920 2-s2.0-68149132103 10.4049/jimmunol.0900796
107. Chang D. H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S. D., Jagannath S., Dhodapkar M. V., Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006 108 2 618 621 2-s2.0-33745961875 10.1182/blood-2005-10-4184 (Pubitemid 44061362)
108. Song W., van der Vliet H. J. J., Tai Y. T., Prabhala R., Wang R., Podar K., Catley L., Shammas M. A., Anderson K. C., Balk S. P., Exley M. A., Munshi N. C., Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clinical Cancer Research 2008 14 21 6955 6962 2-s2.0-58149241014 10.1158/1078-0432.CCR-07-5290
109. Webb T. J., Giuntoli R. L. II, Rogers O., Schneck J., Oelke M., Ascites specific inhibition of CDId-mediated activation of natural killer T cells. Clinical Cancer Research 2008 14 23 7652 7658 2-s2.0-59449106344 10.1158/1078-0432.CCR-08-1468
110. Shimizu K., Goto A., Fukui M., Taniguchi M., Fujii S. I., Tumor cells loaded with α -galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. Journal of Immunology 2007 178 5 2853 2861 2-s2.0-33847369755 (Pubitemid 46333163)
111. Shimizu K., Kurosawa Y., Taniguchi M., Steinman R. M., Fujii S. I., Cross-presentation of glycolipid from tumor cells loaded with α -galactosylceramide leads to potent and long-lived T cell-mediated immunity via dendritic cells. Journal of Experimental Medicine 2007 204 11 2641 2653 2-s2.0-35748954102 10.1084/jem.20070458 (Pubitemid 350063944)
112. Gonzalez-Aseguinolaza G., van Kaer L., Bergmann C. C., Wilson J. M., Schmieg J., Kronenberg M., Nakayama T., Taniguchi M., Koezuka Y., Tsuji M., Natural killer T cell ligand α -galactosylceramide enhances protective immunity induced by malaria vaccines. Journal of Experimental Medicine 2002 195 5 617 624 2-s2.0-0037018103 10.1084/jem.20011889 (Pubitemid 34461506)
113. Cerundolo V., Silk J. D., Masri S. H., Salio M., Harnessing invariant NKT cells in vaccination strategies. Nature Reviews Immunology 2009 9 1 28 38 2-s2.0-58149104377 10.1038/nri2451
114. Courtney A. N., Nehete P. N., Nehete B. P., Thapa P., Zhou D., Sastry K. J., α -Galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 2009 27 25-26 3335 3341 2-s2.0-67349170777 10.1016/j.vaccine.2009.01.083
115. Guillonneau C., Mintern J. D., Hubert F. X., Hurt A. C., Besra G. S., Porcelli S., Barr I. G., Doherty P. C., Godfrey D. I., Turner S. J., Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3330 3335 2-s2.0-62549116236 10.1073/pnas.0813309106
116. Ko S. Y., Ko H. J., Chang W. S., Park S. H., Kweon M. N., Kang C. Y., α -Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. Journal of Immunology 2005 175 5 3309 3317 2-s2.0-23844523426